Efficacy of High-Dose Liraglutide as an Adjunct for Weight Loss in Patients with Prior Bariatric Surgery

Obesity Surgery

Volumn 28, Issue 11, 2018, Pages 3553-3558

  Rye, Peter ^a   Modi, Renuca ^b,c   Cawsey, Sarah ^b,c   Sharma, Arya M ^b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ROYAL ALEXANDRA HOSPITAL   (Canada)

Author keywords

Adjustable gastric band; Bariatric surgery; Liraglutide; Obesity; Roux en Y gastric bypass; Sleeve gastrectomy

Indexed keywords

LIRAGLUTIDE; INCRETIN;

ADULT; AGED; ANOREXIA; ARTICLE; BARIATRIC SURGERY; BODY MASS; BODY WEIGHT LOSS; CELLULITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHAGIA; EPIGASTRIC PAIN; ERUCTATION; FATIGUE; FEMALE; GASTRIC BANDING; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; LOSS OF APPETITE; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MUSCLE SPASM; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREOPERATIVE CARE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; ROUX-EN-Y GASTRIC BYPASS; VOMITING; YOUNG ADULT; ADOLESCENT; DRUG EFFECT; MORBID OBESITY;

ADOLESCENT; ADULT; AGED; BARIATRIC SURGERY; HUMANS; INCRETINS; LIRAGLUTIDE; MIDDLE AGED; OBESITY, MORBID; RETROSPECTIVE STUDIES; WEIGHT LOSS; YOUNG ADULT;

EID: 85050225802     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-018-3393-7     Document Type: Article

References (18)

1. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–34
2. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37
3. Sjostrom CD, Lissner L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res. 1999;7:477–84
4. De Gara CJ, Karmali S. The anatomy of a weight recidivism and revision bariatric surgical clinic. Gastroenterol Res Pract. 2014;2014:721095
5. Karmali S, Brar B, Shi X, et al. Weight recidivism post-bariatric surgery: a systematic review. Obes Surg. 2013;23(11):1922–33
6. Sheppard CE, Lester ELW, Chuck AW, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis. 2017;13(3):491–500. Impact of Weight Regain. Gastroenterology Research and Practice. 2013;2013:379564
7. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013;37(11):1443–51
8. Novo Nordisk Canada Inc. Saxenda® Product Monograph. [Internet]. 2017 [cited 2018 Feb 5]. Available from: http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Saxenda_PM_English.pdf
9. European Medicines Agency. Guideline on Clinical Evaluation of Medicinal Products used in Weight Control. [Internet]. 2014 [cited 2018 Feb 5]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170278.pdf
10. Pajecki D, Halpern A, Cercato C, et al. Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery. Rev Col Bras Cir. 2013;40(3):191–5
11. Creange C, Lin E, Ren-Fielding C, et al. Use of liraglutide for weight loss in patients with prior bariatric surgery. Surg Obes Relat Dis. 2016;12(7):S157
12. Gorgojo-martínez JJ, Feo-ortega G, Serrano-moreno C. Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery. Surg Obes Relat Dis. 2016;12(10):1856–63
13. Stanford FC, Alfaris N, Gomez G, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis. 2017;13(3):491–500
14. Lau D et al. Early weight loss responders to liraglutide 3.0 mg had greater weight loss, regression to normoglycemia and reduced T2D development at 3 years vs. early non-responders: SCALE obesity and prediabetes. Can J Diabetes. 2016;40(5):S33
15. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314:687–99
16. Pi-sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22
17. Nuffer WA, Trujillo JM. Liraglutide: a new option for the treatment of obesity. Pharmacotherapy. 2015;35(10):926–34
18. Laferrère B. Bariatric surgery and obesity: influence on the incretins. Int J Obes Suppl. 2016;6(Suppl 1):S32–6